Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
On August 17, Zai Lab Limited American Depositary Shares (ZLAB) and argenx SE (NASDAQ:ARGX) reported positive Phase 3 ALKIVIA study results for VYVGART Hytrulo in autoimmune myositis. VYVGART demonstrated a 15.4-point greater improvement in mean Total Improvement Score (TIS) over placebo in the combined IMNM and dermatomyositis (DM) population, with these benefits persisting through steroid tapering.
The primary endpoint was met with a 14.8-point improvement in IMNM, while DM showed a similar 14.5-point benefit. William Blair's confidence in Vyvgart's path in DM drove ARGX shares up 15% to an all-time high, while RBC Capital raised its price target on Argenx to $1,100, projecting rapid commercial uptake. While ARGX and ZLAB share clinical success through an exclusive licensing agreement in Greater China, their financial profiles differ significantly.
ARGX delivered a 60% year-over-year increase in net product sales to $1.516 billion in Q2 2026, with substantial cash reserves of $5.2 billion. In contrast, ZLAB reported a 3% year-over-year decline in revenue to $106.3 million, alongside an operating loss of $76.5 million, highlighting the substantial financial gap between the two partners.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
